Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Piper Sandler increased their FY2020 EPS estimates for shares of Sarepta Therapeutics in a report issued on Monday, January 11th. Piper Sandler analyst T. Van. Buren now anticipates that the biotechnology company will earn ($8.33) per share for the year, up from their previous forecast of ($9.03). Piper Sandler currently has a “Overweight” rating and a $240.00 target price on the stock. Piper Sandler also issued estimates for Sarepta Therapeutics’ Q4 2020 earnings at ($2.09) EPS, FY2022 earnings at ($3.95) EPS, FY2023 earnings at ($2.50) EPS, FY2024 earnings at $1.30 EPS and FY2025 earnings at $10.30 EPS.
Other equities research analysts have also recently issued reports about the company. Cowen decreased their price target on Sarepta Therapeutics from $213.00 to $114.00 and set an “outperform” rating for the company in a research note on Friday, January 8th. JPMorgan Chase & Co. cut Sarepta Therapeutics from an “overweight” rating to an “underweight” rating and set a $96.00 price target for the company. in a research note on Friday, January 8th. Smith Barney Citigroup cut Sarepta Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday. Robert W. Baird decreased their price target on Sarepta Therapeutics from $223.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, January 8th. Finally, Mizuho cut their price objective on Sarepta Therapeutics from $204.00 to $158.00 and set a “buy” rating on the stock in a report on Friday, January 8th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and sixteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $160.38.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($2.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.89) by ($0.61). The firm had revenue of $143.92 million for the quarter, compared to the consensus estimate of $133.69 million. Sarepta Therapeutics had a negative return on equity of 53.02% and a negative net margin of 117.80%. Sarepta Therapeutics’s quarterly revenue was up 45.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.14) EPS.
Several hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Asset Management Inc grew its stake in shares of Sarepta Therapeutics by 2.5% in the third quarter. CIBC Asset Management Inc now owns 2,796 shares of the biotechnology company’s stock valued at $393,000 after buying an additional 69 shares in the last quarter. US Bancorp DE grew its stake in Sarepta Therapeutics by 4.3% during the 3rd quarter. US Bancorp DE now owns 2,439 shares of the biotechnology company’s stock worth $343,000 after purchasing an additional 100 shares in the last quarter. Spearhead Capital Advisors LLC grew its stake in Sarepta Therapeutics by 6.4% during the 3rd quarter. Spearhead Capital Advisors LLC now owns 1,871 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 113 shares in the last quarter. OneAscent Financial Services LLC grew its stake in Sarepta Therapeutics by 4.1% during the 4th quarter. OneAscent Financial Services LLC now owns 3,379 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 133 shares in the last quarter. Finally, Pathstone Family Office LLC grew its stake in Sarepta Therapeutics by 270.9% during the 3rd quarter. Pathstone Family Office LLC now owns 204 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 149 shares in the last quarter. 92.70% of the stock is owned by institutional investors and hedge funds.
In other news, insider Joseph Bratica sold 1,115 shares of Sarepta Therapeutics stock in a transaction on Friday, December 11th. The stock was sold at an average price of $165.00, for a total value of $183,975.00. Following the completion of the sale, the insider now directly owns 9,255 shares of the company’s stock, valued at $1,527,075. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.90% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.